![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
Pharmacokinetic Interaction of HCV NA5A Inhibitor MK-8742 and Ketoconazole in Healthy Subjects
|
|
|
Reported by Jules Levin
15th International Workshop on Clinical Pharmacology of HIV & Hepatitis Therapy, Washington DC; May 19-21, 2014
WW Yeh1, WL Marshall1, P Auger2, L Caro1, P Jumes1, X Huang1, D Dreyer1, H-P Feng1, D Swearingen2, S Azzam2, A Hohnstein2, C Brandquist2 and JR Butterton1
1Merck & Co., Inc., Whitehouse Station, NJ, USA; 2Celerion, Tempe, AZ, USA
![Pharm1.gif](../images/052514/052514-5/Pharm1.gif)
![Pharm2.gif](../images/052514/052514-5/Pharm2.gif)
![Pharm3.gif](../images/052514/052514-5/Pharm3.gif)
![Pharm4.gif](../images/052514/052514-5/Pharm4.gif)
![Pharm5.gif](../images/052514/052514-5/Pharm5.gif)
![Pharm6.gif](../images/052514/052514-5/Pharm6.gif)
![Pharm7.gif](../images/052514/052514-5/Pharm7.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|